# Laboratorios Ojer Pharma S.L.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/laboratorios-ojer-pharma-s-l

- Industry: Pharmaceuticals
- Headquarters: Pamplona, Spain
- Website: www.ojerpharma.com
- Total disclosed funding: $2.7M
- Latest round: Seed (Jan 1, 2020)
- Investors on record: 3

## About

Laboratorios Ojer Pharma S.L. is a Spanish pharmaceutical company focused on developing innovative treatments for dermatological conditions in both human and veterinary medicine.Founded in 2005 and based in Pamplona, Spain, Laboratorios Ojer Pharma S.L. specializes in the creation of pharmaceutical products. The company has engaged in 8 investment deals, with its most recent funding round completed in March 2023, raising EUR 2.3 million from investors including Clave Capital, Dozen Investments, Easo Ventures, and Inveready Asset Management.Laboratorios Ojer Pharma specializes in the development of innovative pharmaceutical products aimed at addressing dermatological conditions in both human and veterinary medicine. The company’s key offerings include bioadhesive gels such as Rhinoheal®, designed to hydrate and restore nasal mucosa, and Lipovir®, the first transparent gel containing acyclovir for treating cold sores. These products are formulated to alleviate symptoms like burning and itching while enhancing healing processes, catering to patients seeking effective dermatological solutions. Ojer Pharma's products are marketed primarily in international markets, including South Korea and Portugal, reflecting the company’s commitment to expanding its geographical footprint. The target clientele consists of healthcare professionals and institutions that require effective dermatological treatments for their patients, thereby addressing significant unmet needs in the healthcare sector.In 2023, Laboratorios Ojer Pharma reported a revenue of EUR 1,639,710.1 with an EBITDA of EUR 289,355.5. The revenue structure is driven by partnerships and direct sales involving its flagship products, Rhinoheal® and Lipovir®. The company engages in business-to-business (B2B) transactions, collaborating with pharmaceutical distributors and healthcare providers to deliver its innovative products.In March 2023, Laboratorios Ojer Pharma S.L. raised EUR 2.3 million in venture funding to further consolidate the commercialization of its products, complete regulatory procedures, and support the development of new patentable vehicle innovations. The company plans to expand its product offerings and enter new markets, focusing on regions such as Asia and Europe. The funds will directly support these initiatives, enhancing the company's capabilities in the competitive pharmaceutical landscape.

## Funding rounds

- Seed, Jan 1, 2020, $1.1M — Dozen Investments
- Seed, Jul 17, 2014, $0.8M — Inveready Asset Management
- Seed, Jun 8, 2011, $0.7M — Fundacion Caja Navarra

## Investors

- Fundacion Caja Navarra (https://capitalatlas.ai/funds/fundacion-caja-navarra) — Seed
- Inveready Asset Management (https://capitalatlas.ai/funds/inveready-asset-management) — Seed
- Dozen Investments (https://capitalatlas.ai/funds/dozen-investments) — Seed